Advances in immunotherapy for breast cancer
10.3760/cma.j.cn371439-20231017-00038
- VernacularTitle:乳腺癌免疫治疗研究进展
- Author:
Qiang SA
1
;
Hangcheng XU
;
Jiayu WANG
Author Information
1. 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院内科，北京 100021
- Keywords:
Breast neoplasms;
Immunotherapy;
Immune checkpoint inhibitors;
Neoadjuvant therapy
- From:
Journal of International Oncology
2024;51(4):227-234
- CountryChina
- Language:Chinese
-
Abstract:
According to the latest global cancer burden data for 2020 released by the WHO's International Agency for Research on Cancer, breast cancer has become the malignant tumor with the highest incidence worldwide. Based on existing internal medicine treatment means like chemotherapy, targeted therapy and endocrine therapy, the development of immunotherapy provides novel solutions for the treatment of breast cancer. To date, the clinical research of immunotherapy in various molecular types and stages of breast cancer has reached certain achievements. In addition, the exploration of joint application with other therapies, predictive markers for efficacy, and immune-related adverse effects is also ongoing. The research and development in the field of breast cancer immunotherapy holds a promising prospect, and approaching research advances will promote the further application of immunotherapy in breast cancer.
